It is my pleasure to share some exciting news. Effective today, Twist Bioscience has acquired Genome Compiler, with the intent to pair our capabilities in software design with Twist’s innovative DNA synthesis platform. The acquisition yields a service offering that delivers seamless design and build of synthetic DNA. We believe the biology community will find the integrated offering a great platform to accelerate research efforts.
Our existing customers will continue to enjoy the Genome Compiler platform on our website, www.genomecompiler.com, and you can expect continuing high levels of support for your research. As we move forward, the Genome Compiler team will be a core component in building out the integrated Twist Bioscience design-build capabilities.
Twist Bioscience is commercializing a disruptive DNA synthesis platform that utilizes the power of silicon to deliver unprecedented throughput. They completed their alpha access program last year, delivering over 65 million base pairs in the first six months of commercial activities, and are now in the process of validating a new and improved chip that will offer unmatched DNA synthesis capacity, rapid turnaround time, and an industry leading price point. With their beta access program underway and delivery of the first customer shipments in March, Twist Bioscience expects market leading gene production levels by the summer.
For more information about Twist Bioscience, to learn more about the transaction or to learn about our beta access program please visit www.twistbioscience.com. We look forward to working with you as part of our new organization.